Almirall opens the week with a clear consensus view, shares trade steadily in Madrid

By Anna Wagner, Analysts & Consensus desk. Reviewed prior to publication on 2026-06-30, 09:39.

Almirall (ES0157097017) begins this week with its shares trading on the Bolsa de Madrid, reflecting a stable view from the local Spanish market. The focus for investors on Tuesday is the established analyst consensus on the stock, which frames expectations for the remainder of 2026.

What analysts focus on

Analyst coverage on Almirall typically centers on its recurring prescription revenues in dermatology and immunology, where visibility on patient volumes and reimbursement regimes is comparatively robust. Most houses track metrics such as EBITDA margin, net debt levels and pipeline progress in autoimmune skin diseases when updating their models.

Consensus data services usually show a distribution of recommendations across Buy, Hold and Sell, with an average 12-month price target that reflects expected prescription growth and cost discipline in Spain and other European markets. The implied upside or downside in these targets is closely watched whenever macro assumptions or regulatory conditions in key markets change.

A consistent Tuesday consensus angle

On a Tuesday consensus-focus day, investors often look at how Almirall compares with European specialty pharma peers such as Galapagos or UCB in terms of earnings visibility and pipeline risk. The relationship between the consensus EBITDA margin and the guided figures in recent quarterly communication is used as a gauge for management credibility.

In addition, rating changes or target price revisions from larger international houses like Goldman Sachs, JPMorgan or UBS can tighten or widen the consensus range, even if Almirall itself remains a mid-cap name on the Spanish exchange rather than a constituent of a pan-European blue-chip index.

The product behind the stock

Almirall generates a large share of its revenue from prescription dermatology treatments, including well-established topical therapies for conditions such as psoriasis and atopic dermatitis. In addition, the group markets systemic therapies in immunology and other specialty areas, giving it a diversified portfolio within European specialty pharma.

Where the stock trades today

The Almirall shares (ES0157097017) trade on 2026-06-30, 09:30 on the Bolsa de Madrid at an indicative level in euros, with the price providing context for the prevailing analyst consensus and any recalibration of recommendations.

This article is for informational purposes only and does not constitute investment advice or a recommendation to buy or sell securities. All figures and assessments are based on publicly available information believed to be reliable at the time of writing, but may change without notice.